期刊簡介 | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱![]() | Molecular Cancer LetPub Score 8.5
52 ratings
Rate
Reputation 8.6 Influence 8.3 Speed 8.7 | ||||||||||||||||||||||||
期刊簡稱 | MOL CANCER | ||||||||||||||||||||||||
ISSN | 1476-4598 | ||||||||||||||||||||||||
h-index | 103 | ||||||||||||||||||||||||
CiteScore |
| ||||||||||||||||||||||||
自引率 (2023-2024) | 2.20%自引率趨勢 | ||||||||||||||||||||||||
掲載範囲 |
| ||||||||||||||||||||||||
官方網站 | http://molecular-cancer.biomedcentral.com | ||||||||||||||||||||||||
在線稿件提交 | https://submission.nature.com/new-submission/12943/3 | ||||||||||||||||||||||||
開放訪問 | Yes | ||||||||||||||||||||||||
出版商 | BioMed Central | ||||||||||||||||||||||||
主題領域 | 医学 | ||||||||||||||||||||||||
出版國/地區 | ENGLAND | ||||||||||||||||||||||||
發行頻率 | 月刊 | ||||||||||||||||||||||||
創刊年 | 2002 | ||||||||||||||||||||||||
每年文章數 | 165每年文章數趨勢 | ||||||||||||||||||||||||
黃金OA百分比 | 100.00% | ||||||||||||||||||||||||
OA Related Info![]() | APC: Yes( EUR3990; USD4890; GBP3490; ) APC waiver:Check Notes Other charges: No Keywords: oncology、tumour biology、cancer antigens Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | ||||||||||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q1
| ||||||||||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1476-4598%5BISSN%5D | ||||||||||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Average 2 Month(s) | ||||||||||||||||||||||||
競爭力 * | 來自作者的數據: About 50% | ||||||||||||||||||||||||
參考鏈接 |
| ||||||||||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
|
首頁 上一頁 1 2 3 4 5 6 7 下一頁 末頁 (頁 | |
[Molecular Cancer] 的評論 | 撰寫評論 |
作者: 慈悲冬晴 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-12-18 18:18:11 評論於 How long did it take for the news to come later? ![]() ![]() |
作者: Phoebe Law 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-11-23 09:37:27 評論於 I couldn't find enough reviewers for my paper either ![]() ![]() |
作者: 魔都吉星 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-11-14 08:16:26 評論於 I am also doing major revisions, raising about 60 questions, and currently supplementing experiments to improve experimental methods. May I ask what kind of tumor you are researching? ![]() ![]() |
作者: 擒龙盼雁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-11-10 15:34:20 評論於 Review speed: 3.0 | Submission hit rate: 5.0 Emphasis on research direction: tumor Experience sharing: 3 months major revision, raised more than 30 questions, need to supplement some experiments, currently still supplementing experiments. Can you please tell me the probability of being accepted after the major revision? ![]() ![]() |
作者: 崇学小姐姐 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-11-08 15:38:45 評論於 Editor appointed for a month already, is there such a situation... Feeling that the current submission interface is a bit different from what the seniors shared ![]() ![]() |
作者: Leila Bernard 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-11-05 17:13:17 評論於 I am the 8th day directly showing 2 reviewers accepted ![]() ![]() |
作者: 魔都吉星 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-31 21:48:54 評論於 Have you received it yet? ![]() ![]() |
作者: 凌霄迎波 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-31 20:16:07 評論於 I submitted it for review in just one day ![]() ![]() |
作者: 崇学小姐姐 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-27 21:29:12 評論於 The current submission status is "Editor appointed"... There is no editor assigned as mentioned by the seniors. May I ask how many days it will take for review? ![]() ![]() |
作者: 崇学小姐姐 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-27 09:43:30 評論於 Can you share the status changes? Thank you, boss ![]() ![]() |
作者: 凌霄迎波 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-23 16:44:31 評論於 How long does it take to receive it after the repair? ![]() ![]() |
作者: 凌霄迎波 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-23 13:35:39 評論於 Finally received after four months. I hope the magazine will get better and better ![]() ![]() |
作者: 崇学小姐姐 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-22 18:35:15 評論於 How long does it take for a fast rejection? What is the status after the editor is appointed and the submission is sent for review? ![]() ![]() |
作者: Esther Vaughan 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-19 22:27:48 評論於 It's very difficult to get selected, definitely not the kind of level where you can just coast along. Without a solid amount of work, you'll basically be rejected immediately ![]() ![]() |
作者: 无名氏121 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-15 20:40:59 評論於 Since its inception, Chongqing Medical University has published a total of 10 articles, with no instances of multiple articles from the same department ![]() ![]() |
作者: 泽语大叔 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-12 22:08:21 評論於 Certainly, building a reputation takes a long time to accumulate, but it can be destroyed in just a few articles ![]() ![]() |
作者: 重阳悦爱 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-10 18:18:30 評論於 Indeed, many around me are quick to reject without hesitation, and it is not easy to share research on top of that ![]() ![]() |
作者: 南风怡嘉 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-10 08:03:23 評論於 The quality of the articles currently is much worse than the domestic STTT ![]() ![]() |
作者: 泽语大叔 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-09 20:41:27 評論於 Research focus: circRNA; tumors; epigenetic experiences: have been paying attention to the Research series articles of this journal for a year, and I am happy to see the editorial department discover problems and adjust directions. Currently, there has been a significant increase in the research direction and regional distribution of manuscript sources, and each issue is filled with a lot of excellent scientific research. Indeed, some work may still look inferior to the impact factor, but overall, I think it is steadily improving. I hope the journal will continue to improve! ![]() ![]() |
作者: 泽语大叔 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-09 13:47:32 評論於 It has been a year since the Research series articles of this journal received attention. The editorial team is happy to discover and adjust their direction, and the research direction and regional distribution of the current manuscripts have significantly improved compared to before. Each issue also contains a large amount of impressive research work. Although there are still some works that pale in comparison to the impact factor, overall the quality is steadily improving, and we hope the journal continues to get better! ![]() ![]() |
作者: 泽语大叔 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-09 13:21:22 評論於 It has been a year since the Research series articles of this journal have been attracting attention. The editorial department is happy to discover and adjust its direction even if there are problems. Currently, the research direction and geographical distribution of the manuscript sources have been greatly improved compared to before, and each issue is filled with plenty of impressive scientific research work. Admittedly, some work still seems to fall short of the impact factor, but overall, things are moving in a positive direction. I hope the journal continues to improve! ![]() ![]() |
作者: 泽语大叔 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-09 11:41:13 評論於 It has been a year since the Research series articles of this journal have been in focus. The editorial team is happy to make adjustments and changes to the direction, even if problems are discovered. Currently, there has been a significant increase in the research direction and regional distribution of submissions compared to before, and each issue is filled with a large number of impressive research works. Admittedly, some works still seem to fall short of the impact factor, but overall it is steadily improving. Hoping for the magazine to become even better! ![]() ![]() |
作者: 泽语大叔 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-08 21:47:41 評論於 Review Speed: 12.0 | Submission Hit Rate: 25.0 Emphasis Research Direction: Tumor; Epigenetic Genetics Shared Experience: It has been a year since focusing on the Research series articles of this journal. The editorial department is thrilled to discover and adjust the direction, and there has been a significant increase in the research direction and regional distribution of the manuscript sources. Each issue also presents plenty of outstanding scientific research. Admittedly, some work may seem inferior to the Impact Factor, but overall, the journal is steadily improving. Wishing the magazine continued success! ![]() ![]() |
作者: 上清奥雅 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-09-13 16:08:48 評論於 Review speed: 3.0 | Submission acceptance rate: 25.0 Major research focus: Tumor; CAF experience sharing: Challenging ![]() ![]() |
作者: Phoebe Law 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-09-05 21:07:43 評論於 What original data is included? ![]() ![]() |
首頁 上一頁 1 2 3 4 5 6 7 下一頁 末頁 (頁 |
Contact us